首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1688篇
  免费   75篇
  国内免费   1篇
电工技术   13篇
化学工业   207篇
金属工艺   23篇
机械仪表   48篇
建筑科学   33篇
矿业工程   2篇
能源动力   27篇
轻工业   163篇
水利工程   5篇
石油天然气   6篇
无线电   79篇
一般工业技术   136篇
冶金工业   916篇
原子能技术   6篇
自动化技术   100篇
  2023年   7篇
  2022年   24篇
  2021年   37篇
  2020年   23篇
  2019年   29篇
  2018年   27篇
  2017年   46篇
  2016年   38篇
  2015年   33篇
  2014年   40篇
  2013年   64篇
  2012年   61篇
  2011年   76篇
  2010年   53篇
  2009年   41篇
  2008年   39篇
  2007年   31篇
  2006年   27篇
  2005年   23篇
  2004年   18篇
  2003年   22篇
  2002年   15篇
  2001年   9篇
  2000年   13篇
  1999年   40篇
  1998年   264篇
  1997年   169篇
  1996年   112篇
  1995年   50篇
  1994年   53篇
  1993年   54篇
  1992年   5篇
  1991年   13篇
  1990年   13篇
  1989年   11篇
  1988年   12篇
  1987年   20篇
  1986年   10篇
  1985年   10篇
  1984年   3篇
  1983年   3篇
  1982年   5篇
  1981年   6篇
  1980年   9篇
  1978年   3篇
  1977年   25篇
  1976年   74篇
  1965年   1篇
  1964年   1篇
  1955年   1篇
排序方式: 共有1764条查询结果,搜索用时 31 毫秒
1.
2.
3.
An endocrine testing center (ETC) is a universal requirement for the practice of endocrinology. Modifications of the Mayo Clinic model for an ETC should be applicable to most endocrine practices. Key components of an ETC include a centralized testing area, registered nurse-physician team, detailed testing protocols, and patient education programs.  相似文献   
4.
5.
Relapse after autologous bone marrow transplantation for chronic myelogenous leukemia (CML) can be due either to the persistence of leukemia cells in systemic tissues following preparative therapy, or due to the persistence of leukemia cells in the autologous marrow used to restore marrow function after intensive therapy. To help distinguish between these two possible causes of relapse, we used safety-modified retroviruses, which contain the bacterial resistance gene NEO, to mark autologous marrow cells that had been collected from patients early in the phase of hematopoietic recovery after in vivo chemotherapy. The cells were then subjected to ex vivo CD34 selection following collection and 30% of the bone marrow were exposed to a safety-modified virus. This marrow was infused after delivery of systemic therapy, which consisted of total body irradiation (1,020 cGy), cyclophosphamide (120 mg/kg), and VP-16 (750 mg/m2). RT PCR assays specific for the bacterial NEO mRNA, which was coded for by the virus, and the bcr-abl mRNA showed that in two evaluable CML patients transplanted with marked cells, sufficient numbers of leukemia cells remained in the infused marrow to contribute to systemic relapse. In addition, both normal and leukemic cells positive for the retroviral transgenome persisted in the systemic circulation of the patients for at least 280 days posttransplant showing that the infused marrow was responsible for the return of hematopoiesis following the preparative therapy. This observation shows that it is possible to use a replication-incompetent safety-modified retrovirus in order to introduce DNA sequences into the hematopoietic cells of patients undergoing autologous bone marrow transplantation. Moreover, this data suggested that additional fractionation procedures will be necessary to reduce the probability of relapse after bone marrow transplantation in at least the advanced stages of the disease in CML patients undergoing autologous bone marrow transplantation procedures.  相似文献   
6.
In previous studies, dolasetron was shown to have both renal and hepatic elimination mechanisms. This study was conducted to determine the impact of varying degrees of hepatic dysfunction on the pharmacokinetics and safety of dolasetron and its reduced metabolites. Seventeen adults were studied: six healthy volunteers (group I), seven patients with mild hepatic impairment (Child-Pugh class A; group II), and four patients with moderate to severe hepatic impairment (Child-Pugh class B or C1; group III). Single 150-mg doses of dolasetron mesylate were administered intravenously and orally, with a 7-day washout period separating treatments. After intravenous administration, no differences were observed between healthy volunteers and patients with hepatic impairment in maximum plasma concentration (Cmax), areas under the plasma concentration-time curve (AUC), or elimination half-life (t1/2) of intact dolasetron. No significant differences were found in Cmax, AUC, or apparent clearance (C(lapp)) of hydrodolasetron, the primary metabolite of dolasetron. The mean t1/2 increased from 6.87 hours in group I to 11.69 hours in group III. After oral administration, C(lapp) of hydrodolasetron decreased by 42%, and Cmax increased by 18% in patients with moderate to severe hepatic impairment. There were less changes in patients with mildly hepatic impairment. Total percentage of dose excreted as metabolites was similar for healthy volunteers and patients with hepatic impairment, although urinary metabolite profiles differed slightly. Dolasetron was well tolerated and there were no apparent differences in adverse effects between groups or treatments. Because hepatic impairment did not influence Cl(app) of hydrodolasetron after intravenous administration, and the range of plasma concentrations of hydrodolasetron after oral administration was not different from those observed in healthy volunteers, dosage adjustments are not recommended for patients with hepatic disease and normal renal function.  相似文献   
7.
There are several tumors and tumorlike entities of bone that do not easily fit into the specific classifications provided elsewhere in this issue. In this article, several seemingly unrelated entities are discussed, including cystic diseases of bone (simple bone cysts and aneurysmal bone cysts), Langerhans' cell histiocytosis, benign and malignant vascular tumors of bone, and adamantinoma of long bone and its relationship to osteofibrous dysplasia.  相似文献   
8.
9.
This Review article ponders core/shell structured nanoparticles that can be prepared with features that combine properties of different materials, including ligands that enhance their biocompatibility. These nanocomposites are not classified in terms of synthesis, but rather by how these features are distributed in the final morphology, attending to connected or isolated materials that end up in interacting or not‐interacting functionalities. In particular, we have focused on magnetic core/shell‐structured particles with a directly connected, coupled, or isolated second functionality. The current progress on methods in colloidal solution that have allowed the great development of these multifunctional magnetic and active spheres on biological and biomedical fields is reported.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号